Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 16 April 2021, including: adenovirus vaccines and blood clots; Lilly’s new moves in genetic diseases; efficacy debate over Chinese COVID vaccines; putting a price tag on innovation; and Sanofi’s bullishness on IL-2.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino" - Scrip, 15 Apr, 2021.)
(Also see "Lilly Takes Another Leap Into Gene Therapy With Jaguar" - Scrip, 13 Apr, 2021.)
(Also see "Sinovac Real World Data Shed Fresh Light On China COVID Vaccine Efficacy Debate" - Scrip, 14 Apr, 2021.)
(Also see "Do R&D Spending And Approvals Really Measure Innovation?" - Scrip, 13 Apr, 2021.)
(Also see "Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days" - Scrip, 12 Apr, 2021.)